We are actively seeking research and licensing partners and research collaborations to fully leverage the experience of our team in clinical development and strategy across atopic, respiratory, and immunoe-inflammatory diseases. These may include small molecules to augment the transformational potential of our KINect® platform for drug discovery, and biologic product candidates such as monoclonal and bi-specific antibodies. Specific areas of interest include:
- Kinases inhibitors for autoimmune diseases, such as rheumatoid arthritis, chronic inflammation disease (e.g. inflammatory bowel disease), autoinflammatory diseases (e.g. CAPS, Stills Disease), and cancer.
- New therapeutic applications for our cysteinome-targeted chemical library representing 60% of the kinome.
- Biologic product candidates targeting validated pathways in immune-inflammatory diseases, including in respiratory and dermatology settings